UPCOMING EVENTS: AAOS - March 14-18 | BASK - March 14-18 | BBA - May 4-6 | EWMA - May 4-6
Our range of regenerative medicine solutions focuses on innovative human tissue products supplying high quality Allografts designed to make a difference to clinicians and patients whilst honouring the gift of donation.
The Allosource range includes room temperature Allografts such a Human Acellular Dermal Matrix, an Acellular alternative to Xenograft dermal skin substitutes and grafts for wound care.
Supplying innovative temporary burns skin and Acellular Allografts designed as skin replacement, not substitution.
AvoMed are working on the product development and commercialisation plans of several soon to be launched projects in field of Advanced Woundcare.
The Regenerative medicine market is expected to reach USD 38.70 Billion by 2021 from USD 13.41 Billion in 2016 at a CAGR of 23.6%. The global market is segmented into cell-based products and acellular products. The cell-based products is expected to dominate the global market in 2016.
Based on therapy, the market is segmented into cell therapy, gene therapy, tissue engineering, and immunotherapy. Immunotherapy is the fastest growing segment in the global market.
This market is also segmented by application. By application, the segments are orthopaedic and musculoskeletal disorders, dermatology, cardiology, diabetes, central nervous system diseases, and other applications. Oncology is the fastest growing application market in the global market in 2016.
